𝔖 Bobbio Scriptorium
✦   LIBER   ✦

High-dose ara-C and etoposide in refractory or relapsing acute leukemia

✍ Scribed by Mathias Freund; Hartmut Link; Helmut Diedrich; Sebastian LeBlanc; Hans-Jochen Wilke; Hubert Poliwoda

Publisher
Springer
Year
1991
Tongue
English
Weight
424 KB
Volume
28
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

High-dose liposomal daunorubicin and hig
High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia
✍ Jorge Cortes; Elihu Estey; Susan O'Brien; Francis Giles; Yu Shen; Charles Koller πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 89 KB πŸ‘ 2 views

## Background: Liposomal encapsulation of daunorubicin (daunoxome, dnx; nexstar pharmaceutical, boulder, co) changes the pharmacology profile to increase delivery to tumor sites and decrease toxicity. the authors investigated the effect of daunorubicin in combination with ara-c in patients with ref

Treatment of relapsed and refractory acu
Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide
✍ Martin Gore; Ray Powles; Anil Lakhani; Sarah Milan; Jennifer Maitland; Glen Goss πŸ“‚ Article πŸ“… 1989 πŸ› Springer 🌐 English βš– 425 KB

A total of 65 patients under the age of 55 with acute leukaemia received high-dose cytosine arabinoside (Ara-C) in combination with high-dose etoposide without an anthracycline. Complete remission rates for patients with relapsed or refractory acute myelogenous leukaemia (AML) were 15/25 (60%) and 1

Treatment of relapsed or refractory acut
Treatment of relapsed or refractory acute leukemia in childhood with bisantrene combined with high dose aracytine
✍ Leblanc, Thierry ;DemΓ©ocq, FranΓ§ois ;Leverger, Guy ;Baruchel, AndrΓ© ;Lemerle, So πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 542 KB

## Abstract Bisantrene is an anthracene derivative which has demonstrated activity in acute myeloblastic leukemia (AML) and in lymphoma. The present study was designed to assess the reinduction rate and toxicity of bisantrene (250 mg/m^2^/d Γ— 5) associated with aracytine (1000 mg/m^2^ twice a day Γ—